Free Trial

Lyell Immunopharma (LYEL) Insider Trading & Ownership

Lyell Immunopharma logo
$0.64 -0.01 (-1.01%)
(As of 02:22 PM ET)

Lyell Immunopharma (NASDAQ:LYEL) Insider Buying and Selling Activity

Current
Insider Ownership
Percentage
25.10%
Number Of
Insiders Buying
(Last 3 Years)
0
Number Of
Insiders Selling
(Last 3 Years)
1
Amount Of
Insider Selling
(Last 3 Years)
$71,040.00
Get LYEL Insider Trade Alerts

Want to know when executives and insiders are buying or selling Lyell Immunopharma stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily.

LYEL Insider Buying and Selling by Quarter

Lyell Immunopharma Insider and Congressional Trades History

Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/23/2022Richard KlausnerDirectorSell11,100$6.40$71,040.00  
(Data available from 1/1/2013 forward)

LYEL Insider Trading Activity - Frequently Asked Questions

The list of insiders at Lyell Immunopharma includes Richard Klausner. Learn more on insiders at LYEL.

25.10% of Lyell Immunopharma stock is owned by insiders. Learn more on LYEL's insider holdings.

Lyell Immunopharma Key Executives

  • Dr. Richard D. Klausner M.D. (Age 72)
    Founder & Executive Chairman
    Compensation: $80k
  • Dr. Lynn Seely M.D. (Age 65)
    Ph.D., President, CEO & Director
    Compensation: $962.23k
  • Mr. Charles W. Newton (Age 53)
    Chief Financial Officer
    Compensation: $744.74k
  • Mr. Stephen J. Hill (Age 54)
    Chief Operating Officer
    Compensation: $775.97k
  • Dr. Gary Lee Ph.D. (Age 47)
    Chief Scientific Officer
    Compensation: $889.68k
  • Mr. Matthew Lang J.D. (Age 48)
    Chief Business Officer, Chief Legal Officer & Corporate Secretary
    Compensation: $596.25k
  • Prof. Stanley R. Riddell M.D.
    Founder & Scientific Advisor
  • Dr. Crystal L. Mackall M.D. (Age 63)
    Founder & Scientific Advisor
  • Nellie Dillery
    Director of Accounting
  • Ms. Ellen Rose
    Senior Vice President of Communications & Investor Relations


This page (NASDAQ:LYEL) was last updated on 12/18/2024 by MarketBeat.com Staff
From Our Partners